Hikma presents R&D pipeline of more than 330 products

By Public Technologies
  • Hikma Pharmaceuticals has more than 330 products in development, targeting an addressable market exceeding $100 billion.
  • Epinephrine nasal spray is slated for US filing in the second half of 2026.
  • Generic Ellipta dry powder inhaler filing is targeted for 2029, addressing an approximately $11 billion market.
  • Generic Respimat soft mist inhaler filing is targeted for 2028, addressing an approximately $2 billion market.
  • Low global warming potential pressurized metered-dose inhalers are targeted for filing in 2028, addressing an approximately $9 billion market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk